54741_Image_jpeg.jpg
Daxor’s Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care
August 04, 2021 08:30 ET | Daxor Corporation
Data Led to Multi-Center Study In Progress At Three Leading Hospitals Oak Ridge, TN, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume...
54741_Image_jpeg.jpg
Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)
April 29, 2021 08:31 ET | Daxor Corporation
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility...
54741_Image_jpeg.jpg
Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
December 10, 2020 08:30 ET | Daxor Corporation
NEW YORK, NY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor to Present at the 2020 MicroCap Rodeo Best Ideas Bowl
October 12, 2020 08:30 ET | Daxor Corporation
NEW YORK, NY, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
New Research Shows Daxor’s BVA-100® Blood Test Provides Unique Benefit in Detecting Anemia and Heart Failure Risk, Presented at the Heart Failure Society of America Meeting 2020
October 06, 2020 08:30 ET | Daxor Corporation
NEW YORK, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Announces Initiation of First-of-Its-Kind Multicenter BVA-100® Study in Hospitalized Patients With COVID-19
July 15, 2020 08:00 ET | Daxor Corporation
COVID-19 Investigation Commences at NYU Langone Health with Daxor’s Blood Volume Analysis Technology NEW YORK, July 15, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment...
54741_Image_jpeg.jpg
Daxor Corporation’s BVA-100® Test Used to Guide Treatment In COVID-19 Patient
March 20, 2020 08:00 ET | Daxor Corporation
New Clinical Protocol for Volume-Guided Therapy Helps Combat Coronavirus NEW YORK, March 20, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative...
54741_Image_jpeg.jpg
New Data Presented on Blood Volume at Annual Heart Failure Society Meeting Amid Call to Broadly Adopt Daxor’s Diagnostic Technology
September 18, 2019 08:00 ET | Daxor Corporation
NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation Announces the Acquisition of the BVA-100® Blood Volume Analyzer by a Leading Academic Health Center in the Pacific Northwest
August 06, 2019 08:00 ET | Daxor Corporation
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation to Present at the LD Micro 9th Annual Invitational on June 4th, 2019
May 31, 2019 08:00 ET | Daxor Corporation
NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...